

European Respiratory Society Annual Congress 2013

Abstract Number: 3812

Publication Number: P484

Abstract Group: 4.3. Pulmonary Circulation and Pulmonary Vascular Disease

Keyword 1: Pulmonary hypertension **Keyword 2:** Hypoxia **Keyword 3:** Circulation

Title: TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats

Ms. Shujin 23405 Guo shujinguo@126.com MD¹, Ms. Tao 23406 Wang 13616585@qq.com¹, Mr. Guangming 23407 He 182392953@qq.com¹, Ms. Dan 23408 Xu 3637126@qq.com¹ and Prof. Dr Fuqiang 23409 Wen wenfuqiang@126.com¹. ¹ Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China, 610041 .

Body: Objectives: Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by remodelling of pulmonary vasculature. This study aimed to investigate the therapeutic effects of TRAM-34, a selective blocker of the intermediate-conductance Ca²⁺-activated K⁺ channel (Kca3.1), on hypoxia-induced PAH in rats. Methods: Pulmonary artery smooth muscle cells (PASMCs) were used to measure Kca3.1 mRNA and protein expression in response to normoxia (21%O₂) and hypoxia (2%O₂) for 24 hours. Flow cytometry was performed after administering TRAM-34. In vivo experiment, TRAM-34 (i.p.-injection) was administered daily to Wistar rats over a period of 3 weeks starting on the day of hypoxia (10%O₂, 23h/d). Mean pulmonary artery pressure (mPAP) and right ventricle hypertrophy index (RVHI) were assessed. Tissue samples were collected for histological analysis. Result: Quantitative real-time PCR and western blot showed that Kca3.1 mRNA and protein expression were increased in PASMCs after hypoxia. The difference was significant (p<0.05) respectively. Hypoxia reduced the proportion of PASMCs in the G0/G1 phase (65% vs 76.2%). TRAM-34 inhibited PASMCs proliferation by G0/G1 arrest. In the hypoxia group, TRAM-34 intervention reduced the mPAP (20±1 mmHg vs 17±1 mmHg, p<0.05) and RVHI (41.5%±3.8% vs 33.6±3.2%, p<0.05). The ratio of wall area and lumen area attenuated after TRAM-34 administration. The difference was significant (p<0.05) compared with the normoxia group. Conclusion: TRAM-34 attenuates hypoxia-induced PASMCs proliferation, and reduces pulmonary artery remodelling in vivo. These findings raise the possibility that blocking the Kca3.1 channel will attenuate hypoxia-induced PAH, and thus TRAM-34 offer a new approach to PAH therapy.